TEOA Inhibits Proliferation and Induces DNA Damage of Diffuse Large B-Cell Lymphoma Cells Through Activation of the ROS-Dependent p38 MAPK Signaling Pathway

Xingxing Yu,Xin Wang,Xu Wang,Yi Zhou,Yanchun Li,Aiwei Wang,Tongtong Wang,Yihan An,Weidong Sun,Jing Du,Xiangmin Tong,Ying Wang
DOI: https://doi.org/10.3389/fphar.2020.554736
IF: 5.6
2020-09-04
Frontiers in Pharmacology
Abstract:Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma, accounting for approximately 30% to 40% of non-Hodgkin's lymphomas (NHL). The administration of rituximab significantly improved the outcomes of DLBCL; however, the unavoidable development of resistance limits the long-term efficacy. Therefore, a new generation of less toxic drugs with higher chemotherapy response is required to prevent or reverse chemoresistance. TEOA is a pentacyclic triterpenoid compound isolated from the roots of <i>Actinidia eriantha</i>. Studies have confirmed that TEOA has significant cytotoxicity on gastrointestinal cancer cells. However, there are no relevant reports on DLBCL cells. In this study, we investigated the potential molecular mechanism of the anticancer activity of TEOA in DLBCL cells. The results demonstrated that TEOA inhibited proliferation and induced apoptosis in time-and dose-dependent manners. TEOA induced reactive oxygen species (ROS) generation, which was reversed by N-acetyl cysteine (NAC). TEOA induced DNA damage, increased the level of γ-H2AX, and the phosphorylation of CHK1 and CHK2. In addition, TEOA induced the activation of the p38 MAPK pathway and pretreated with p38 inhibitor SB20358 or ROS scavenger could block TEOA-induced DNA damage. Taken together, these results suggest that ROS mediated activation of the p38 MAPK signal pathway plays an important role in initiating TEOA-induced DNA damage.
pharmacology & pharmacy
What problem does this paper attempt to address?
The paper aims to investigate the mechanism of action of a pentacyclic triterpenoid compound named TEOA (2α,3α,24-trihydroxyurs-12-en-24-oic acid) on diffuse large B-cell lymphoma (DLBCL) cells. The main objectives include: 1. **Exploring the anti-proliferative effect of TEOA**: Study the inhibitory effect of TEOA on the proliferation of DLBCL cells and its dose- and time-dependent relationship. 2. **Revealing the mechanism of TEOA-induced apoptosis**: By detecting the expression changes of apoptosis-related proteins (such as caspase-3, PARP, etc.), and using a pan-caspase inhibitor to verify whether apoptosis is dependent on the caspase pathway. 3. **Elucidating the pathway of TEOA-induced DNA damage**: Observe whether TEOA induces DNA damage by activating the ROS (reactive oxygen species)-dependent p38 MAPK signaling pathway, and explore the relationship between p38 MAPK activation and DNA damage repair in this process. 4. **Evaluating the synergistic effect of TEOA with chemotherapeutic drugs**: Study the therapeutic effect of TEOA in combination with commonly used chemotherapeutic drugs (such as vincristine and cyclophosphamide) to discover its potential synergistic effects. Through these studies, the paper hopes to provide new candidate drugs for the treatment of DLBCL and gain a deeper understanding of its potential molecular mechanisms.